Introduction

Biomarkers may help influence long-term outcomes of psoriatic disease by improving the objective assessment of the presence and severity of psoriatic arthritis (PsA) and by guiding treatment selection. However, there are no validated biomarkers for PsA.

Areas covered

Beginning with a brief overview of the clinical features of PsA and concepts about biomarkers and risk prediction in medicine, this narrative review covers the recent developments in the field of PsA biomarker research including biomarkers for identifying patients with psoriasis who are at high risk for developing PsA, for PsA diagnosis, joint damage, treatment response, and disease activity. The limitations of current research and potential solutions for the near future are discussed.

Expert opinion

Although some progress is being made, a concerted international collaborative effort by all stakeholder – patients and advocacy organizations, clinicians, researchers, industry partners, and regulatory agencies with adequate funding ideally from a private–public partnership will be required such that robust biomarkers for this heterogeneous disease are brought to market. Use of multi-omic approaches with innovative data collection and analytic technologies is beginning and in conjunction with novel targeted therapies portend a bright future for patients with psoriatic disease.

中文翻译：

---

银屑病关节炎生物标志物发现的途径。

简介

生物标志物可以通过改善对银屑病关节炎 (PsA) 的存在和严重程度的客观评估以及指导治疗选择来帮助影响银屑病疾病的长期结果。然而，PsA 没有经过验证的生物标志物。

覆盖区域

从简要概述 PsA 的临床特征以及有关生物标志物和医学风险预测的概念开始，这篇叙述性评论涵盖了 PsA 生物标志物研究领域的最新进展，包括用于识别具有患 PsA 高风险的银屑病患者的生物标志物，用于 PsA 诊断、关节损伤、治疗反应和疾病活动。讨论了当前研究的局限性和不久的将来的潜在解决方案。

专家意见

尽管正在取得一些进展，但需要所有利益相关者——患者和倡导组织、临床医生、研究人员、行业合作伙伴和监管机构共同努力，并从公私合作伙伴关系中获得足够的资金，以便为此建立强大的生物标志物异种疾病被推向市场。使用具有创新数据收集和分析技术的多组学方法正在开始，并且与新的靶向疗法相结合预示着银屑病患者的光明未来。